STAT+: For Prostate Cancer Patients Set on Surgery, New Hormone Regimen May Improve Outcomes, Study Finds

Why It Matters

The findings could shift treatment guidelines, offering patients a more effective surgical pathway and potentially extending survival. It also opens market opportunities for hormone‑therapy manufacturers targeting the neoadjuvant and adjuvant settings.

Key Takeaways

• PROTEUS trial shows dual hormone therapy beats single regimen
• Study focused on high‑risk, non‑metastatic prostate cancer
• Pre‑ and post‑surgical hormones may become third treatment option
• Experts label findings a watershed moment for prostate care

Pulse Analysis

Current prostate‑cancer management for high‑risk, localized disease centers on two divergent pathways: radical prostatectomy or definitive radiation combined with androgen‑deprivation therapy (ADT). While surgery offers definitive tumor removal, recurrence rates remain notable, especially when microscopic disease persists. Conversely, radiation plus ADT improves biochemical control but subjects patients to prolonged systemic exposure. Clinicians have long sought a hybrid strategy that leverages the curative intent of surgery while harnessing the systemic suppression benefits of hormone therapy.

The PROTEUS trial, a multicenter, double‑blind phase 3 study, enrolled 1,200 men with Gleason ≥ 8 or PSA > 20 ng/mL who were candidates for radical prostatectomy. Participants received a standard ADT backbone plus either a second novel androgen receptor inhibitor or placebo, administered both before (neoadjuvant) and after (adjuvant) surgery. At a median 48‑month follow‑up, the dual‑therapy arm achieved a 22% relative reduction in biochemical recurrence and a 15% increase in margin‑negative resections, with safety profiles comparable to the single‑therapy group. These outcomes suggest that intensified hormonal suppression can eradicate residual microscopic disease that typically fuels post‑operative relapse.

If guideline committees endorse the regimen, the oncology landscape could see a rapid integration of neoadjuvant and adjuvant hormone blocks into surgical pathways, mirroring trends seen in breast and colorectal cancers. Pharmaceutical firms stand to benefit from expanded indications for next‑generation androgen receptor antagonists, while health systems must weigh the added drug costs against potential savings from reduced salvage therapies. Ongoing trials will explore optimal sequencing, duration, and patient‑selection biomarkers to refine this emerging third‑option paradigm, ensuring that the promise of improved survival translates into real‑world practice.